In 174 client-owned cats with CKD, Elura was well tolerated over a 56 day study².

• Multi-center, placebo-controlled, randomized and masked field study.
• Elura™ administered at 2 mg/kg once daily.
• The most common adverse reactions were vomiting, hypersalivation, inappetence, behavior change and lethargy.

Elura™ was tested in healthy cats for 6 months in a target animal safety study, supporting safety at the label dose.

• Randomized, placebo-controlled laboratory study in 32 intact cats aged approximately 11 months.
• Observations included dose-dependent increases in salivation and intermittent vomiting. Decreased lymphocyte count was observed only in cats administered Elura™; increased mean corpuscular volume (MCV) and increased triglycerides were more common in cats receiving Elura™.

In a 32-day telemetry study in 8 healthy cats Elura™ was well tolerated, supporting the safety profile².

• A telemetry device was implanted for continuous monitoring of cardiovascular variables and blood glucose.
• Vehicle control administered once daily for 3 days followed by Elura™ 2mg/kg once daily for 28 days.
• Observations included transient decreases in heart rate and direct blood pressure (systolic, diastolic and mean arterial), which reversed when they were handled. Transient increases in blood glucose were observed

*A multi-center, placebo controlled, randomized and masked field study including 176 cats with CKD and at least 5% unintended loss of body weight (as compared to the highest weight in the medical records for the 3 years preceding enrollement). 4/10 cats in the control group maintained or gained weight. Study period was 56 days (Day 0 – Day 55). Primary endpoint was change in weight at Day 55.

INDICATION: Elura™ is indicated for management of weight loss in cats with chronic kidney disease.

IMPORTANT SAFETY INFORMATION: For oral use in cats only. Do not use in cats that have a hypersensitivity to capromorelin, or in cats with hypersomatotropism (acromegaly). Elura™ may increase serum glucose for several hours after dosing; use in cats with current or historical diabetes mellitus has not been evaluated and may not be appropriate. Use with caution in cats that may have cardiac disease, severe dehydration, or hepatic dysfunction. Elura™ has not been evaluated in cats younger than 5 months of age, or in breeding, pregnant or lactating cats. The most common adverse reactions included vomiting, hypersalivation, inappetence, behavior change and lethargy.

References